Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5895485 | 0.91 | MEN1 (0.37) | — | |
| SCHEMBL5897155 | 0.84 | OPRD1 (0.41) | OPRD1OPRK1GPR119STSACHE | |
| SCHEMBL29381025 | 0.81 | PKM (0.39) | GPR119PKMSMN1; SMN2 | |
| SCHEMBL5895249 | 0.78 | PKM (0.47) | GPR119PKMSMN1; SMN2 | |
| SCHEMBL5895758 | 0.78 | USP2 (0.41) | OPRD1OPRK1GPR119PKMSMN1; SMN2 | |
| SCHEMBL29857824 | 0.76 | CYP4F2 (0.37) | PKMSMN1; SMN2 | |
| SCHEMBL29382858 | 0.76 | PKM (0.38) | GPR119PKMSMN1; SMN2 | |
| SCHEMBL29857826 | 0.76 | CYP4F2 (0.37) | PKMSMN1; SMN2 | |
| SCHEMBL23247143 | 0.75 | CYP4F2 (0.36) | PKMSMN1; SMN2 | |
| SCHEMBL23246690 | 0.74 | PKM (0.43) | PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091211-B2 | Cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR5, CXCR1, ACKR3 | OPRD1 129/4885OPRK1 163/4885GPR119 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.